DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 4 days (NewC4)
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 4 days - (New C4)
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
azacitidine Resistant: B - Late Trials
|
azacitidine Resistant: B - Late Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
venetoclax + midostaurin Resistant: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
cytarabine Resistant: C3 – Early Trials
|
cytarabine Resistant: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
venetoclax + gilteritinib Resistant: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
venetoclax + sorafenib Resistant: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
decitabine Resistant: C3 – Early Trials
|
decitabine Resistant: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
quizartinib Sensitive: C3 – Early Trials
|
quizartinib Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
CML
|
DNMT3A mutation
|
CML
|
YD312 Resistant: C3 – Early Trials
|
YD312 Resistant: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
decitabine/cedazuridine Sensitive: C3 – Early Trials
|
decitabine / cedazuridine Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
CRC
|
DNMT3A mutation
|
CRC
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
DNMT3A mutation
|
T Cell Non-Hodgkin Lymphoma
|
DNMT3A mutation
|
T Cell Non-Hodgkin Lymphoma
|
lenalidomide Resistant: C3 – Early Trials
|
lenalidomide Resistant: C3 – Early Trials
|
DNMT3A mutation
|
NSCLC
|
DNMT3A mutation
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
DCAG Sensitive: C3 – Early Trials
|
DCAG Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
RVU120 Sensitive: C3 – Early Trials
|
RVU120 Sensitive: C3 – Early Trials
|
DNMT3A mutation
|
Peripheral T-cell Lymphoma
|
DNMT3A mutation
|
Peripheral T-cell Lymphoma
|
CHOP Resistant: C3 – Early Trials
|
CHOP Resistant: C3 – Early Trials
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
EPZ-5676 Sensitive: D – Preclinical
|
EPZ-5676 Sensitive: D – Preclinical
|
DNMT3A mutation
|
AML
|
DNMT3A mutation
|
AML
|
ABBV-744 Sensitive: D – Preclinical
|
ABBV-744 Sensitive: D – Preclinical
|